Ceribell, INC

CeriBell, Inc. announced second quarter 2026 financial results, showcasing a 33% year-over-year revenue increase to $28.1 million, driven by strong account growth and product adoption.

CeriBell, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of two Class II directors and the ratification of its independent auditor.

CeriBell, Inc. announced first quarter 2026 financial results, showcasing a 29% year-over-year revenue increase to $26.5 million and raising full-year revenue guidance.

CeriBell, Inc. announced robust financial results for Q4 and full year 2025, driven by significant revenue growth and critical FDA regulatory milestones.

Ceribell, Inc. announced its LVO stroke detection and monitoring solution received FDA Breakthrough Device Designation, positioning it as the first point-of-care EEG technology for this indication.

CeriBell, Inc. announced the resignation of Lucian Iancovici from its Board of Directors, effective December 31, 2025, citing a focus on other professional ventures.

CeriBell, Inc. announced a 33% increase in total revenue for the second quarter of 2026, reaching $28.1 million, but reported a net loss of $19.3 million.

CeriBell, Inc. announced its first quarter 2026 financial results, showing a 29% increase in total revenue driven by product and subscription growth, while also detailing ongoing investments in R&D and sales.

CeriBell, Inc. reported a significant increase in net loss for Q3 2025 and the nine months ended September 30, 2025, despite robust growth in both product and subscription revenues, while also initiating patent infringement litigation.

CeriBell, Inc. announced significant revenue increases for Q2 2025, driven by product and subscription growth, but also reported a substantial rise in net losses and operating expenses.

CeriBell, Inc. announces a 42% increase in total revenue for the first quarter of 2025, fueled by growth in both product and subscription revenue.

CeriBell, Inc. announced its financial results for the third quarter of 2024, highlighting significant revenue growth driven by increased product and subscription sales.

CeriBell, Inc. announced a 36% revenue increase to $89.1 million in 2025, driven by expanded adoption of its AI-powered Ceribell System and new FDA clearances for delirium and pediatric/neonatal seizure monitoring, despite continued net losses.

CeriBell's 10-K filing reveals a 45% revenue increase in 2024, driven by wider adoption of its Ceribell System for neurological condition diagnosis.

Xingjuan Chao, President and CEO and a Director of Ceribell, Inc., reported multiple transactions in common stock on August 13, 2026.

Joseph Michael Taylor, a Director of Ceribell, Inc., sold 13,095 shares of common stock on August 13, 2026 for $23.40 per share.

Xingjuan Chao, President and CEO and a Director of Ceribell, Inc., sold 39,000 shares of common stock on August 3, 2026 for $18.32 per share.

Thomas A. West, a Director of Ceribell, Inc., received 16,011 shares of common stock on July 28, 2026.

Sharon O'Keefe, a Director of Ceribell, Inc., received 16,011 shares of common stock on July 28, 2026.

Xingjuan Chao, Director and President/CEO of Ceribell, Inc., reported transactions involving the sale and acquisition of common stock and stock options on July 7, 2026, executed under a Rule 10b5-1 trading plan.

CeriBell, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 2, 2026, to elect directors and ratify auditor appointment.

Ceribell, Inc. has filed an amendment to its 2025 Annual Meeting Proxy Statement to correct a numerical error in the disclosure of principal accountant fees and services.

Ceribell, Inc. has filed a definitive proxy statement with the SEC.

CeriBell, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 10, 2025, to elect directors and ratify the appointment of its independent accounting firm.

CeriBell, a medical technology company focused on neurological diagnostics, is set to launch its initial public offering, offering 10,606,060 shares with an expected price range of $16.00 to $17.00 per share.

Ceribell, Inc. introduces its 2024 Incentive Award Plan to attract, retain, and motivate key personnel through equity ownership opportunities.

CeriBell, Inc. has filed an amended S-1 registration statement detailing its corporate governance structure, bylaws, and other key information in preparation for its initial public offering.

Ceribell, a medical technology company, files an S-1 registration statement for an IPO to further its point-of-care EEG platform in acute care settings.

TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, has reported a joint beneficial ownership of 2,975,566 shares, representing 7.8% of Ceribell, Inc.'s common stock.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 15.0% of Ceribell Inc.'s common stock as of June 30, 2026.

BlackRock, Inc. has reported beneficial ownership of 5.03% of Ceribell Inc.'s common stock as of June 30, 2026.

Global Value Investment Portfolio Management Pte Ltd and associated entities report a 4.2% stake in CeriBell, Inc. as of March 31, 2026.

Xingjuan Chao reports beneficial ownership of 1,893,995 shares of CeriBell, Inc. common stock, representing 4.9% of the outstanding shares as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 12.9% of Ceribell Inc.'s common stock as of March 31, 2026.